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1.INTRODUCTION
 2 
1.1. The Complement System 
 
In 1896 the complement system was discovered and named after its objective to 
“complement” antibodies in their function to kill bacteria (1). The complement system is an 
essential part of the innate immune system and is composed of three independent but 
connected pathways that share a common purpose. They are called the classical, alternative, 
and mannose-binding lectin pathway. The complement system acts as a first line of defense to 
recognize and destroy pathogens and modified self-antigens, bridge the innate and adaptive 
immune systems, and eliminate immune complexes and products subsequent to inflammatory 
injury (2,3). The way in which the complement proteins help destroy pathogenic 
microorganisms and soluble antigens is by inducing an inflammatory response themselves 
(realized by anaphylatoxins, most notably C3a and C5a), thereby promoting chemotaxis, 
leukocyte activation and vasodilation. Complement components also serve as opsonins by 
marking antigens and thus enhance phagocytosis by phagocytic cells like macrophages. 
Terminal complement components also have the ability to directly kill unencapsulated, gram-
negative pathogens by disrupting the cell membrane (1). 
The complement system is composed of more than 30 plasma and membrane-
associated proteins, and their function can be broken down into three units. The first unit 
represents proteins that activate the system, the second group of proteins has a regulatory 
function, and the last group acts as membrane-associated receptors that respond to 
complement components created during the activation. Complement proteins of the classical 
pathway are referred to by numbers (C1-9), of the alternative pathway by letter symbols (for 
example Factor H or D) and membrane-associated complement proteins often by trivial 
names (2). Predominantly produced by the liver, many complement plasma proteins are in an 
inactive state and only become active proteases after enzymatic cleavage (also called 
zymogens). Those proteases in turn exert their enzymatic activity on other zymogens down 
the complement pathway and thereby initiate a rapid complement response. The fragments of 
the cleaved proteins are designated with lowercase suffixes – for example C3 is cleaved into 
C3a and C3b (1,2). 
As already mentioned there are three different proteolytic pathways known to activate 
complement. Even though they are distinctive in their mechanism of activation and target 
recognition, they ultimately converge at C3 which results in the formation of C3a, C3b, C5a 
and the membrane attack complex (C5b-9) (4) (Figure 1). 
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Figure 1. Overview of the complement cascade 
Adapted from Hochberg M, Gravallese E, Silman AJ, Smolen J, Weinblatt M, Weisman M. 
Rheumatology. 7th ed. Philadelphia:Elsevier; 2007.  
 
 The classical pathway was the one being discovered first, but its activation is 
markedly dependent on a prior humoral immune response, and thus it is the last to have 
evolved. Immune complexes are formed when IgG or IgM immunoglobulins are complexed 
to pathogens or other non-self antigens. The multimeric C1 complex is made up of C1q, C1r 
and C1s molecules. The classical pathway is triggered, when the C1q binds to the Fc tails of 
the IgG or IgM immune complex. In response C1s and C1r go through a conformational 
change that activates and enables them to carry out their enzymatic activity. As a 
consequence, C1s then cleaves C4 and C2 to C4a and C4b as well as C2a and C2b, 
respectively. The assembly of C4b and C2a (C4b2a) generates the C3 convertase of the 
classical pathway, which enzymatically cleaves the central C3 component into C3a and C3b. 
This is the point where all three complement cascades converge. The C5 convertase is 
subsequently formed by the combination of C3b and C4b2a (C4b2a3b). At the same time C3b 
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also serves as an opsonin thus helping phagocytic cells. After C5 is cleaved into C5b and C5a, 
the MAC, that is made up of C5b, C6,C7,C8 and C9, is assembled. The MAC has the abilty to 
disrupt the cell membrane of pathogens which leads to pathogen cell lysis (1,4).  
Unlike the classic pathway, the mannose-binding lectin pathway does not need a 
hummoral immune response to be initiated. The lectin pathway gets activated when mannose 
binding lectin or Ficolin bind to mannose or other carbohydrate residues, respectively. These 
carbohydrate residues are found on the surface of pathogens. MBL and Ficolin are associated 
with other MBL proteins (called MASPs) and exist as a MBL complex in the serum. After the 
complex encounters a mannose residue, there is a conformational change and subsequent 
autoactivation of MASP-1 and MASP-2. These continue to enzymatically cleave C4 and C2 
which results in the assembly of C4b2a and thus formation of a C3 convertase analogous to 
the C3 convertase of the classical pathway (1,4). 
The activation of the alternative pathway is not inititated by a pathogen-binding 
protein like the other pathways. It is continously activated by spontaneous hydrolysis of C3 in 
plasma, also called “tickover”, which produces C3b at a constant rate that is able to target 
bacteria. This hydrolysis can be intensified by contact of C3 with foreign and non-self 
antigens. Only C3b bound to a pathogen initiates binding of Factor B and this is ensued by 
binding of Factor D. Factor D enzymatically cleaves Factor B and C3bBb is formed, which is 
a functional equivalent to the C3 convertase of the classical pathway. A protein called 
properdin, that is made by activated neutrophils, attaches to the C3b part of the C3 convertase 
and stabilizes it. Recent studies have also found that properdin itself can bind to necrotic and 
apoptotic cells and thereby activate the complement cascade (1,4). 
There is a connection between a dysregulated complement system and the 
pathogenesis of rheumatic diseases, most notably rheumatoid arthritis, SLE, APS, 
dermatomyositis, Sjögren syndrome, systemic sclerosis and vasculitides (Table 1). The 
mechanisms by which an aberrant complement response participates in the pathogenesis of 
these diseases are manifold. They result from complement component deficiency, 
overproduction, excessive activation of complement components, or inappropriate action of 
regulatory proteins. The link between autoimmune diseases and the complement system is 
somewhat contradictory: while its activation causes tissue damage in an ongoing disease, its 
deficiency at the same time renders someone more susceptible to the development of an 
autoimmune disease.  
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Table 1. Association between complement components and rheumatic diseases 
 
Disease Complement components associated with 
disease 
Atypical hemolytic uremic syndrome (aHUS) 
 
 
 
ANCA-associated vasculitis 
 
Antiphospholipid syndrome 
 
C3 glomerulopathy and membranoproliferative 
glomerulonephritis (MPGN) 
  
Sjögren syndrome 
 
Systemic lupus erythematosus (SLE) and lupus 
nephritis 
 
C3, factor H, MCP, factor I, Factor B, 
complement factor H-related proteins, 
Thrombomodulin 
 
Alternative pathway 
 
C3, C4, C5, C3a, C4a, MAC 
 
C3, alternative pathway 
 
 
C4A, C4BP 
 
C1q, C1r, C1s, C2, C3, C4, MBL, factor 
D 
Adapted from Hochberg M, Gravallese E, Silman AJ, Smolen J, Weinblatt M, Weisman M. 
Rheumatology. 7th ed. Philadelphia:Elsevier; 2007.  
 
In SLE for example, excessive complement activation leads to immune complex-
induced inflammation and subsequent tissue damage. However individuals with hereditary 
complement deficiencies are more likely to develop SLE, for instance 93% of patients who 
have a C1q deficiency develop lupus (1). Individuals with hereditary C4 and C2 deficiencies 
are also more prone to develop SLE. Likewise acquired deficiencies like the production of 
autoantibodies against C1q as well as decreased levels of C3 and C4 can be noticed in SLE 
patients and are thought to participate in the development of the disease. C3 and C4 levels are 
even acknowledged means by which SLE disease activity is measured (also in the form of 
disease scoring systems, for example the systemic lupus erythematosus disease activity index 
incorporates hypocomplementemia as a laboratory variable) (5). The lack of key complement 
components leads to defective clearance of immune complexes that subsequently deposit in 
multiple organs and vessels, thereby causing tissue damage and vasculitis. The absence of 
certain complement components also causes defective clearance of apoptotic cells and 
abnormal recognition of self-antigens by B cells (loss of immune tolerance), which eventually 
leads to the development of autoimmunity (4). 
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Recent in vivo studies have shown that the activation of the complement cascade, 
especially the classical pathway, is an essential mediator of pregnancy morbidity and the 
thrombogenic effect of aPL antibodies, and that C3a, C5a and C5b-9 MAC, are key 
components of this process (7). Studies have also shown that due to complement activation, 
patients with primary APS present with hypocomplementemia (decreased C3 and C4 and 
increased C3a and C4a levels) (6). Therefore, complement components may serve as targets 
and be of great significance in the light of novel therapy approaches (7,8). 
 
1.2. Rheumatologic autoimmune diseases: Systemic Lupus Erythematosus and     
       Antiphospholipid Syndrome 
 
 Autoimmune disease describes the process of the immune system attacking self-
antigens secondary to the loss of immunologic tolerance (9). The immunologist Paul Ehrlich 
used the term “horror autotoxicus” in the 20th century to illustrate how catastrophic the idea of 
the body’s immune system turning against his own tissues was, back then thinking that it was 
not compatible with life (10). Present-day believes suggest that an interplay of genetic 
susceptibility as well as environmental factors contribute to the dysregulation of the immune 
system that ultimately leads to tissue destruction (11). There is a differentiation between the 
physiologic self-reactivity necessary for maintaining healthy immune system homeostasis that 
can protect against infection and the pathologic self-reactivity that is commonly known to 
result in a clinically manifested autoimmune disease. They can be classified as systemic, one 
of them being Systemic Lupus Erythematosus, or organ-specific, one of them being 
Antiphospholipid Syndrome. Systemic disease is characterized by the immune system 
attacking ubiquitously expressed self-antigens, while in organ specific disease the self-
antigens are limited to a specific cell or tissue type. In both, autoantibodies, T cells and 
various other immune cells are the culprit of end-organ damage with pathophysiologies being 
very diverse amongst different diseases (12). 
 SLE causes the production of autoantibodies to nuclear antigens (ANA) and a very 
broad clinical picture that ranges from milder manifestations like skin rashes and non-erosive 
arthritis to severe complications such as lupus nephritis or neuropsychiatric disorders. The 
principal pathologies are inflammation, vasculitis, immune complex and subsequent 
complement deposition, and vasculopathy, the latter especially occurring in the presence of 
antiphospholipid antibodies (13). 
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 APS is characterized by a hypercoagulable state with repeated venous, arterial and 
small-vessel thrombosis as well as pregnancy complications in the presence of 
antiphospholipid antibodies (14). It may exist as an isolated disease (primary APS) or in 
association with other rheumatic diseases, primarily SLE, also known as secondary APS (12). 
It is estimated that 30-40% of SLE patients are positive for antiphospholipid antibodies (15). 
 
1.2.1. Systemic lupus erythematosus, the “disease with a thousand faces” (16), is a 
chronic multisystem autoimmune inflammatory disease that clinically presents with wide-
ranging manifestations. Biochemically it is characterized by immune complex formation and 
ANA as well as anti-double stranded DNA antibodies. For the diagnosis of systemic lupus 
erythematosus these antibodies have the greatest sensitivity and specificity, respectively (12). 
 The reported incidence and prevalence of systemic lupus erythematosus varies greatly 
which is due to different populations being studied as well as different methodological 
approaches used amongst studies for identifying cases of SLE. Estimated prevalence varies 
from 20 to 240 per 100,000 persons, while incidence varies from 1 to 10 per 100,000 person-
years (17). Most commonly affected populations are women of childbearing age (15-45 years) 
as well as populations of nonwhite ethnicity and race like African-Americans, Asians, and 
Hispanics (12). 
The definite mechanisms that lead to the development of SLE continue to be very 
elusive. It is most likely attributable to an interplay of genetic variations and environmental 
triggers that make a person more susceptible to the development of this disease. Nowadays it 
is established that disease-associated genetic susceptibility affects almost all components of 
both the innate and adaptive immune system, which in turn are responsible for the 
development of SLE and also for the subsequent susceptibility to environmental factors (12). 
Some of these components are the loss of immunotolerance and a high antigenic load. 
Likewise the excess of type 2 T helper cells  and insufficient B cell suppression are 
responsible for the B cell overactivity and the generation of autoantibodies with subsequent 
immune complex formation (13). Research has also shown that variants in the HLA region on 
chromosome 6 encoding glycoproteins, known as MHC, makes people more susceptible to 
the development of SLE. Particularly the HLA-DRB1 in the class II region shows a strong 
association. These glycoproteins play a major role in antigen presentation. The complement 
system assumes a two-faced role in the pathogenesis of SLE. Development of SLE displays 
an association with genetic deficiencies of early complement pathway components. The 
strongest association can be found with homozygous deficiencies of the components C1q, C4 
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and C2 with subsequent development of SLE in >90%, 50% and 10-20% of cases, 
respectively. At the same time paradoxically the complement system, especially the classical 
pathway, is being activated in patients with SLE and represents a cause of tissue damage. 
Therefore complement component levels are also used to measure disease activity (1,18). 
As mentioned before, environmental influences and certain risk factors also play a role 
in triggering SLE apart from the genetic predisposition. The female to male ratio of 9:1 found 
in the childbearing period already points to hormonal and reproductive contributions as risk 
factors. Studies have shown that lupus patients had significantly higher levels of estradiol and 
prolactin in addition to lower levels of androgens (19). From all the environmental triggers 
linked to SLE, exposure to ultraviolet light has a definite role in the pathogenesis. UV light 
can lead to flares with systemic symptoms and signs of the disease (20). Also, a positive 
relation between oral contraceptive use, postmenopausal hormone replacement therapy and 
SLE incidence has been established (21). There might also be a connection to past Epstein-
Barr Virus infection since SLE patients show significantly higher seropositivity rates (22). 
The risk of developing SLE is also significantly increased in current smokers (23), people 
being treated with lupus-inducing medication like hydralazine or procainamide (24) and with 
exposure to crystalline silica (25). 
The clinical picture of SLE is very heterogenous as is the clinical course with periods 
of remissions and relapses. The disease may involve virtually any organ system in the body. 
The most common symptoms are constitutional with pronounced fatigue, fever, loss of 
appetite and weight, and malaise (Table 2). Almost just as often patients complain of 
musculoskeletal symptoms. Particularly arthtralgias most commonly manifest as the 
presenting symptom of the disease. Arthritis and joint pain usually affect small joints of the 
hand, wrist and knee. Other symptoms are non erosive arthritis, avascular osteonecrosis, 
myalgias and myositis. Also worth mentioning is iatrogenic osteoporosis and subsequent 
fractures due to longstanding glucocorticoid therapy (1,26). 
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Table 2. Approximate prevalence of selected symptoms, signs, and laboratory abnormalities 
in SLE 
Symptoms, sign, or laboratory abnormality                                Prevalence (%) 
Positive antinuclear antibody 
Malaise and fatigue 
Arthralgia, myalgia 
Sun sensitivity, skin changes 
Cognitive dysfunction 
Low C3 or C4 complement 
Fever caused by lupus 
Antibodies to ds DNA 
Arthritis 
Leukopenia 
Pleuritis 
Anemia 
Alopecia 
Nephritis, proteinuria 
Anticardiolipin antibody 
Malar rash 
CNS 
Increased gamma globulin 
Weight loss caused by lupus 
Raynaud phenomenon 
Hypertension 
Sjögren syndrome 
Oral ulcerations (mouth, nose) 
Myositis 
Avascular necrosis 
97 
90 
90 
70 
70 
61 
57 
50 
50 
46 
44 
42 
40 
40 
35 
35 
32 
32 
27 
25 
25 
25 
20 
10 
10 
Adapted from Hochberg M, Gravallese E, Silman AJ, Smolen J, Weinblatt M, Weisman M. 
Rheumatology. 7th ed. Philadelphia:Elsevier; 2007.  
 
Lupus was historically described as a dermatologic disease and correspondingly has 
prominent dermatologic manifestations (26) (Table 3). Dermatologic features specific to 
lupus can be acute, subacute or chronic discoid. Even though only seen in 30% of pateints, the 
best-known acute dermatologic feature is the malar/butterfly rash with or without a 
disseminated maculopapular eruption. Subacute cutaneous lupus erythematosus usually 
presents as scaling papules/plaques that are diffuse and nonscarring. They resemble psoriasis 
or lichen planus and are associated with autoantibodies to Ro in up to 90% of cases. Other 
manifestations are photosensitivity to ultraviolet radiation, alopecia, mucous membrane 
lesions, oral and nasopharyngeal ulcerations, and discoid lesions. The latter can be part of 
chronic discoid SLE as well as the main pathologic feature in a separate entity called Discoid 
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Lupus Erythematosus, a disease associated with scarring and atrophy exclusively limited to 
the skin without organ involvement. Raynaud phenomenon, periorbital edema, livedo 
reticularis (often associated with elevated aPL or severe vasculitis), panniculits, bullous 
lesions, vasculitic purpura, telangiectasias, and urticaria are other dermatologic manifestations 
found in, but not unique to, SLE (1,26). 
 
Table 3. Skin lesion per modified Gilliam classification – Cutaneous manifestations of SLE 
Types of cutaneous lupus 
Acute cutaneous lupus erythematosus 
Subacute cutaneous lupus erythematosus 
Chronic (discoid) lupus erythematosus 
Seen in <1% of cases: hypertrophic lupus, lupus tumidus, lupus profundus,  
lupus pernio (chilblains), bullous lupus  
Cutaneous manifestations of systemic lupus erythematosus 
Sun sensitivity 
Oral, nasal, or genital ulcerations 
Malar rash 
Hair loss or thinning 
Changes in pigmentation 
Urticaria 
Calcinosis 
Telangiectasias  
 
Cutaneo-vascular manifestations of systemic lupus erythematosus 
Cutaneo-vascular manifestations of lupus 
Cryoglobulinemic vasculitis 
Raynaud phenomenon 
Livedo reticularis  
Erythromelalgias 
Ulceration or gangrene 
Purpura  
 
Adapted from Hochberg M, Gravallese E, Silman AJ, Smolen J, Weinblatt M, Weisman M. 
Rheumatology. 7th ed. Philadelphia:Elsevier; 2007.  
 
One of the most debilitating manifestations is renal involvement, with renal failure 
being a common cause of morbidity and mortality in SLE patients. While almost all patients 
(90%) have renal biopsies that show immune complex and complememt depositions, only 
about 50% of the patients will develop clinically manifest lupus nephritis. Since renal 
dysfunction usually starts within the first 3 years of disease onset, regular screening is vital 
during this period. Aside from the immune complex-mediated glomerulonephritis with 
inflammatory cell infiltration that the vast majority of patients presents with, renal 
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involvement can also manifest als tubulointerstital or vascular disease (1). Often 
tubulointerstital or vascular disease is co-occuring with glomerulonephritis and even up to 
66% of patients have tubulointerstital disease on the renal biopsy specimen (12). Possible 
symptoms of lupus nephritis are hematuria, hypertension, proteinuria (more than 0.5g/day) 
with corresponding low serum albumin and edema, and uremia. Prognosis and exact 
management are based on the extent, activity and pathologic classification of renal disease 
(1). 
Other manifestations of SLE can be neuropsychiatric (headache, psychiatric disorders, 
cognitive dysfunction), gastrointestinal (acute abdominal pain, anorexia, nausea), lympathic 
and hematologic (lymphadenopathy, anemia, leukopenia, thrombocytopenia), 
cardiopulmonary (pleuritic discomfort, myocardial dysfunction, pleural effusion), accelerated 
atherosclerosis (coronary artery disease, cerebral vascular disease, peripheral vascular 
disease), and eyes, ear, nose and throat involvement (keratoconjunctivitis sicca, retinal 
vascular changes, sudden-onset sensorineuronal hearing loss). Aside from the fact that they 
show a greater incidence of hematologic malignancies, patients with SLE are also very 
susceptible to infections due to disease-related and therapeutic reasons (1). 
Laboratory findings in patients with SLE are a high erythrocyte sedimanetation rate, 
normal or only slightly elevated C-reactive protein, cytopenias or other hematologic 
abnormalities like autoimmune hemolytic anemia. Antinuclear antibodies should be assessed 
by indirect immunofluorescence tests and additional differentiaion of antinuclear antibodies 
should take place in the setting of a positive ANA titer (anti-Sm, anti-double-stranded DNA, 
anti-ribosome P, anti-proliferating cell nuclear antigen, anti RNA helicase A, anti-Ro/SSA, -
La/SSB autoantibodies, etc.). Further laboratory tests should include the complement levels of 
C3 and C4, which are especially lowered in active disease, antiphospholipid antibodies and 
lupus anticoagulant so as to assess possible APS (1). To determine the extent of renal 
involvement serum creatinine and glomerular filtration rate should be measured, urinary 
status and sediment examined, and 24-hour urine collected (1,27). Further tests depend on the 
specific symptoms a patient experiences and should be individually adjusted. 
Since SLE is a multisystem disease, it’s diagnosis can be rather difficult. Therefore, 
the diagnosis is mostly established with the help of an experienced rheumatologist on the 
basis of the clinical picture as well as serologic or immunologic testing. Recognizing and 
integrating preclinical aspects like the production of autoantibodies, immune complex 
formation or demographic features can help recognize patients that are still asymptomatic or 
symptomatic but do not meet enough criteria to be classified as SLE.  
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Figure 2. Evolution of criteria classification systems for SLE 
Adapted from Hochberg M, Gravallese E, Silman AJ, Smolen J, Weinblatt M, Weisman M.   
Rheumatology. 7th ed. Philadelphia:Elsevier; 2007.  
 
To help doctors diagnose patients suffering from SLE and to more easily identify 
patients for clinical trials the American College of Rheumatology has released guidelines in 
1971 with revisions in 1982 and 1997 (Figure 2). Consistent with these guidelines a patient is 
classified as having SLE if 4 out of 11 criteria are met and differential diagnoses have been 
excluded. In 2012, the SLICC have revised the ACR guidelines and determined 11 clinical 
and 6 immunologic criteria to classify a patient as having SLE (Figure 2). According to the 
SLICC guidelines a patient is diagnosed with SLE if he has either a positive anti-nuclear or 
anti-double stranded DNA antibody titer in addition to lupus nephritis proven with a renal 
biopsy or if he fulfills 4 of the criteria with at least one being immunological and one clinical. 
SLICC guidelines’ additional criteria are a positive direct Coombs test without having 
hemolytic anemia, lowered complement levels as well as further neurologic and dermatologic 
aspects. Both guidelines are in use and diagnosis can also be made by an experienced 
clinician without the need of fulfilling all the criteria postulated (1). 
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There are several phenotypic subgroups of SLE that can clinically overlap and are not 
mututally exclusive. They are classified according to the coexistence of a certain clinical 
picture and specific autoantibodies: anti-dsDNA antibodies with glomerulonephritis; anti-
Ro/SSA antibodies with SLE, subacute cutaneous lupus, neonatal lupus, Sjögren syndrome 
and primary biliary chirrhosis; antiphospholipid antibodies with SLE accompanied by 
vasculopathy, misscarriages, livedo reticularis and stroke (secondary APS). Lastly there is the 
syndrome of SLE-mixed connective tissue disease overlap with anti-U1 ribonucleoprotein 
antibodies, arthritis, Raynaud phenomenon, myositis as well as pulmonary hypertenesion (1). 
Treatment is based on anti-inflammatory and immunosuppressive agents, DMARDs 
and organ specific treatment. The mainstay of treatment for osteoarticular symptoms are 
NSAIDs that may be combined with hydroxychloroquine, an antimalarial drug belonging to 
the DMARDs. If the response to this treatment is unsatisfying, other DMARDs like 
methotrexate are used (1). For dermatologic manifestations a combination of 
nonpharmacologic and pharmacologic treatment is needed. There is a general advice to use 
sun protection, avoid photosensitizing drugs and stop smoking. Pharmacologic therapy is 
based on topical glucocorticoids and calcineurin inhibitors, systemic antimalarial drugs and 
glucocorticoids (1). First-line treatment for severe cytopenias and cardiopulmonary disease 
are glucocorticoids. Treatment of neuropsychiatric manifestations depends on the presentation 
and can range from supportive/symptomatic therapy with anxiolytics or anticonvulsants, 
immunosuppressive therapy with corticosteroids, azathioprine, or cyclophosphamide to 
anticoagulation with warfarin in case of vascular disease (1). Renal involvement presents 
itself in diverse clinical pictures and thus treatment is individually tailored to every patient 
based on blood pressure measurement, the presence of dyslipidemia as well as specific 
investigations like urinalysis, renal biopsy, serologic testing and daily protein excretion. 
There is an induction and maintenance therapy with a combination of immunosuppressive 
agents and DMARDs like glucocorticoids, mycophenolic acid, cyclophosphamide, 
azathioprine and various other agents. Angiotensin-converting enzyme inhibitors or 
angiotensin receptor blockers are the mainstay of treatment for hypertension while statins are 
used for dyslipidemias (1). In case of positive antiphospholipid antibodies, estrogen-
containing hormonal contraceptives should be avoided and antiplatelet-anticoagulant therapy 
may be added to overcome the thrombotic diathesis (28,29). 
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1.2.2. Antiphospholipid Syndrome is an autoimmune disease associated with arterial 
and venous thrombosis, pregnancy morbidity (fetal loss, premature birth, miscarriage), and 
the presence of a miscellaneous group of autoantibodies called antiphospholipid antibodies. 
The aPLs are lupus anticoagulant, anticardiolipin antibodies, and anti-β2 glycoprotein-I 
antibodies. They mostly target phospholipid-binding proteins instead of phospholipids 
themselves. If there is no other underlying autoimmune disease, it is referred to as “primary” 
APS, while in the presence of SLE or any other autoimmune disease it is denoted “secondary” 
APS (1). 
Even though the prevalence of antiphospholipid antibodies in the general population is 
reported to be somewhere between 1% to 5%, depending on the population studied, only a 
small fraction of those individuals will experience APS (1,30). A couple of epidemiological 
studies suggest that the incidence is around 5 new cases per 100.000 persons per year. 
Prevalence increases with age and in individuals with a chronic disease and is estimated to be 
40 to 50 cases per 100.000 persons (30). Primary APS is responsible for approximately 15% 
of cases of deep vein thrombosis with or without consecutive pulmonary embolism, one third 
of new onset strokes in individuals younger than 50 years, and 10% to 15% of recurrent fetal 
death during pregnancy. Patients with SLE and secondary APS syndrome also suffer from 
thromboembolic events and recurrent pregnancy loss. Antiphospholipid antibodies are found 
in 30% to 40% of patients suffering from SLE, while 10% to 15% of SLE patients show 
clinically significant symptoms of APS. In families with APS a genetic predisposition is the 
probable foundation for disease development and a relationship with human leukocyte antigen 
DR7, DR4, C4 null allele and other gene complexes has been established (1). 
Pathogenesis of APS is not completely understood and the heterogenous nature of 
complications suggests that more than one pathological mechanism contributes to the 
development of the disease (31). Thrombosis is amongst other things due to the interaction of 
aPLs with monocytes, thrombocytes and endothelial cells. The interaction results in a 
prothrombotic phenotype. Since aPLs (“first hit”) in the serum are continuously present and 
thrombosis only comes about occasionally, it was hypothesized that another additional 
thrombophilic event (“second hit”) has to occur. Other mechanisms that lead to thrombosis 
are complement activation by aPLs with excess C3a and C5a generation, interference with 
clotting regulatory proteins, and increased release of neutrophil extracellular traps (1). The 
exact pathophysiology of pregnancy loss is still unknown. One the hand thrombosis seems to 
be a definite mechanism since observational studies have shown placental thrombosis and 
infarction as the etiology of pregnancy loss. On the other hand, not all patients with obstetric 
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APS have placental infarction or vasculopathy and other mechanisms have been suggested by 
in vitro studies. aPLs may interfere with implantation of the trophoblast into the maternal 
uterus and lead to decreased production of human chorionic gonadotropin. Activation of the 
classical pathway of the complement cascade by aPLs was shown to be a causative 
mechanism of pregnancy morbidity since the formed anaphylatoxins (C3a, C5a) promote 
tissue injury in addition to a prothrombotic profile. Another causative process is that anti-β2 
glycoprotein-I antibodies seem to be implicated in defective placentation and the 
displacement of annexin V, which usually has an anticoagulant function for the trophoblast 
(1,31). 
Apart from thromboses and pregnancy morbidity, the clinical picture of APS can also 
present itself with only thrombocytopenia or hemolytic anemia. Any organ can be diseased 
and thus the set of clinical features is extremely diverse. Primary APS can evolve into 
secondary APS with SLE, and some patients that initially present with only SLE go on to 
develop secondary APS (1). 
Venous thrombosis most commonly affects the deep veins of the lower extremities 
and arterial thrombosis most often presents itself as an ischemic stroke or transient ischemic 
attack, although occlusion can happen in any part of the vascular tree like the retinal, 
mesenteric, or peripheral arteries. In the general population fetal loss usually occurs in the 
first trimester as opposed to APS pregnancy morbidity that most commonly manifests itself in 
the second and third trimesters. Apart from fetal loss and distress and premature birth, 
pregnant women may also experience complications like preeclampsia, intrauterine growth 
restriction, premature delivery and others. Cardiac valve abnormalities are a highly prevalent 
feature of APS. Usually it is the mitral valve that shows thickening, nodules and vegetations. 
The abnormalities may lead to stenosis, regurgitation or even emboli causing stroke and TIAs, 
but may also be clinically nonsignificant. Even though there is no pathognomonic skin lesion 
in APS the skin feature most commonly encountered is livedo reticularis. Some of the other 
manifestations are leg ulcers, superficial thrombophlebitis, cutaneous gangrene (usually due 
to occlusion of small arteries), and gangrene of the extremities. Thrombocytopenia, mostly in 
the range of 100000 to 150000 per mm3, is often seen in APS patients and usually does not 
cause hemorrhage. Hemolytic anemia seldom occurs, even though 10% to 20% of the patients 
have a positive Coombs test. Renal involvement in the form of thrombotic microangiopathy 
can lead to renal failure with hypertension and proteinuria (1,31). 
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Catastrophic APS is variant of APS and can lead to multiorgan failure and be 
potentially fatal. It is characterized by positive serology for aPLs and the sudden and 
simultaneous (or within less than a week) start of microvascular thrombosis in at least 3 organ 
sites (1,12). It has been proposed that extensive complement activation contributes to the 
pathogenesis and development of catastrophic APS. This theory is supported by case reports 
of patients that have been successfully treated with eculizumab, a C5 inhibitor, and at the 
same time not being responsive to treatment with anticoagulants (31). 
Diagnosis is based on the Sapporo Criteria that were established in 1966 and revised 
in Sydney 2006 (Figure 3). A patient needs to meet at least one clinical and one laboratory 
criteria to be diagnosed with APS. Clinical criteria are vascular thrombosis and pregnancy 
morbidity, while laboratory criteria are the presence of aPLs measured by a standardized 
ELISA at least 12 weeks apart. 
 
 
Figure 3. Revised Sapporo Classification Criteria for APS 
Adapted from Firestein GS, Budd RC, Gabriel SE, McInnes IB, O’Dell JR. Kelley and 
Firestein’s Textbook of Rheumatology. 10th ed. Philadelphia: Elsevier; 2017. 
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Treatment of APS depends on the clinical picture. aPL positive people that are 
asymptomatic don’t receive treatment. Patients with an acute episode of thrombosis receive 
heparin, while patients with a past thrombotic event receive warfarin for secondary 
prophylaxis. Warfarin can be combined with aspirin in case of recurrent thrombosis. Prgenant 
women that are aPL positive and had a previous fetal loss are treated with unfractioned or 
low-molecular-weight heparin, that can be supplement by low-dose aspirin. 
Thrombocytopenia with a count of less than 50,000/mm3 is treated with prednisone and 
intravenous immunoglobulin. Adequate therapy of catastrophic APS consists of 
anticoagulation, corticosteroids, intravenous immunoglobulin, and plasmapheresis. If there is 
no improvement cyclophosphamide, rituximab, or eculizumab, the latter being a terminal 
complement inhibitor, have been proposed as an alternative treatment option (12). 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
               
  2. OBJECTIVES
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The purpose of the study is to compare complement component levels amongst two 
groups of patients, one group of patients having SLE as a diagnosis, while the other group has 
SLE and secondary APS as a diagnosis. Also, the correlation between complement 
component levels and anti-dsDNA and anticardiolipin autoantibodies has been determined, 
respectively. 
 
 
Hypothesis 
1. Complement component levels in patients with SLE and secondary APS are 
significantly lower compared to patients with SLE without secondary APS. 
2. Complement component levels are related to ds-DNA and anticardiolipin antibodies. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. MATERIALS AND METHODS 
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3.1. Study Design 
This cross-sectional study was conducted in the Department of Immunology and 
Rheumatology of the University Hospital Split (KBC Split) of the University of Split, School 
of Medicine and data were collected from the period of January 2006 to May 2018. 
3.2. Study Population 
 In this study 74 patients were included, from which 45 were diagnosed with SLE and 
29 were diagnosed with SLE and secondary APS. All patients were diagnosed by a 
rheumatologist on the basis of the ACR criteria from 1997 for the classification of SLE and 
on the basis of revised Sapporo Criteria from 2006 for the Classification of APS. Exclusion 
criteria was the diagnosis of any other coexisting rheumatologic disease apart from SLE or 
SLE with secondary APS, respectively. Eligible patients were identified using the database at 
the Department of Immunology and Rheumatology of the University Hospital Split (KBC 
Split). 
3.3. Materials 
 Medical data of eligible patients were retrieved from the Institute of Laboratory 
Diagnostics at the University Hospital Split, location Križine. Following laboratory data were 
collected for each patient, if available:  
1. ANA antinuclear antibodies (positive/negative) 
2. anti-ds DNA antibodies (negative if <30) 
3. C3 (RI 0.9-1.8) 
4. C4 (RI 0.1-0.4) 
5. IgG (RI 6.5-16.0) 
6. IgM (RI 0.5-3.0) 
7. IgA (RI 0.4-3.5) 
8. Lupus Anticoagulant (negative if <1.20) 
9. IgG/IgM anticardiolipin antibodies (negative if <15/12.5) 
10. IgG/IgM beta2-gylcoprotein 1 antibodies (positive if >20) 
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3.4. Statistical Evaluation 
Data analysis was conducted using the statistical software STATISTICA 12 (TIBCO 
Software Inc. v12.0). In this study data has been reproduced in the form of tables and graphs. 
The normal distribution of data has been tested with the Kolmogorov-Smirnov Test. To 
determine the difference and the significance for numeric and normally distributed variables 
between the two studied groups, the T-test has been used. Non-numeric variables were tested 
with Chi-Square test or alternatively with Fisher exact test. The significance level was 
determined to be P < 0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
  4. RESULTS 
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The 45 patients included in the study and diagnosed with SLE have a lowered C3 
complement level that averaged 0.88 (reference interval of 0.9-1.8), with a standard deviation 
of 0.26 and a 95% confidence interval that defines a range of 0,8 to 0,96. In contrast, the C4 
complement level lies within the reference interval (0.10-0.40), nevertheless it is determined 
to be at the lower range of normal with a mean of 0.14, a standard deviation of 0.08, and a 
95% confidence interval that defines a range of 0.11 to 0.16.  
The IgG values, only retrieved in 44 participants, were within the reference interval 
(6.5-16.0) with a mean of 11.87 and a standard deviation of 4.44. (Table 4) 
Table 4. Descriptive Statistics of C3, C4 and IgG for patients with SLE 
Category = SLE Descriptive Statistics  
  Valid N Mean Confidence - -95.000% Confidence - 95.000% Std.Dev. 
C3 45 0.88 0.80 0.96 0.26 
C4 45 0.14 0.11 0.16 0.08 
IgG 44 11.87 10.52 13.21 4.44 
 
 
 
 
 
Patients that are diagnosed with SLE and secondary APS have a C3 complement level 
that lies within the reference interval (0.9-1.8), with a mean of 0.90, and a standard deviation 
of 0.23 as well as a calculated 95% CI of 0.82 to 0.99. Likewise, the C4 complement level lies 
within the reference interval with a mean of 0.12 (RI 0.10-0.40), a standard deviation of 0.07, 
and a 95% CI of 0.10-0.15. Both complement component levels were in fact within the RI, 
but it bears mentioning that both variables were found at the lower border of normal. 
The IgG values, reported in 27 participants, were within the reference interval (6.5-16.0) with 
a mean of 14.76 and a standard deviation of 17.55. (Table 5) 
Table 5. Descriptive Statistics of C3, C4 and IgG for patients with SLE and secondary APS 
Category = SLE + APS syndrome Descriptive Statistics 
  Valid N Mean Confidence - -95.000% Confidence - 95.000% Std.Dev. 
C3 29 0.90 0.82 0.99 0.23 
C4 29 0.12 0.10 0.15 0.07 
IgG 27 14.76 7.82 21.71 17.55 
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The variables gender and diagnosis are not independent. There is a statistically 
significant preponderance of the female gender in both groups (P value = 0.016). (Table 6) 
 
Table 6. Observed gender frequencies  
2-Way Summary Table: Observed Frequencies  
  Gender - Female 
Gender 
- Male 
Row - 
Totals 
SLE + APS syndrome 22 7 29 
% 75.86% 24.14%   
SLE 43 2 45 
% 95.56% 4.44%   
Totals 65 9 74 
Fisher exact test (1-side) 0,0158 
 
 
 
 
In both groups IgG aCL antibody is mostly negative. The Chi-Square test didn’t prove 
that IgG aCL antibody is more specific for any patient group (P = 0.217). (Table 7) 
 
Table 7. Observed IgG aCL antibody frequencies 
2-Way Summary Table: Observed Frequencies  
  
IgG aCL 
Antibody 
- 
negative 
<15 
IgG aCL 
Antibody 
- positive 
Row - 
Totals 
SLE 30 11 41 
% 73.17% 26.83%   
SLE + APS syndrome 14 10 24 
% 58.33% 41.67%   
Totals 44 21 65 
Chi-Square test 0,2170 
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In both groups IgM aCL antibody is mostly negative. The Chi-Square test didn’t prove 
that IgM aCL antibody is more specific for any group of patients (P = 0.863). (Table 8) 
 
Table 8. Observed IgM aCL antibody frequencies 
 
 
 
 
In both groups IgG beta2-glycoprotein 1 Antibody is mostly negative. The fisher exact 
test proves that a negative IgG beta2-glycoprotein 1 Antibody is more specific for the patient 
group diagnosed with SLE (P = 0.011). (Table 9) 
 
Table 9. Observed IgG beta2-glycoprotein 1 antibody frequencies 
2-Way Summary Table: Observed Frequencies  
  
IgG beta2-
glycoprotein 
1 Antibody 
- negative 
IgG beta2-
glycoprotein 
1 Antibody 
- positive 
>20 
Row - 
Totals 
SLE 36 2 38 
% 94.74% 5.26%   
SLE + APS syndrome 9 5 14 
% 64.29% 35.71%   
Totals 45 7 52 
 Fisher exact test (1-side)  0.011 
 
 
 
 
 
2-Way Summary Table: Observed Frequencies  
  
IgM aCL 
Antibody 
- 
negative 
< 12.5 
IgM aCL 
Antibody 
- positive 
Row - 
Totals 
SLE 28 12 40 
% 70.00% 30.00%   
SLE + APS syndrome 18 7 25 
% 72.00% 28.00%   
Totals 46 19 65 
Chi-Square test 0.863 
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In both groups IgM beta2-glycoprotein 1 Antibody is mostly negative. The fisher 
exact test shows that the IgM beta2-gylcoprotein 1 Antibody is not specific for any patient 
group (P = 0.275). (Table 10) 
 
Table 10. Observed IgM beta2-glycoprotein 1 antibody frequencies 
2-Way Summary Table: Observed Frequencies  
  
IgM beta2-
glycoprotein 
1 Antibody 
- negative 
IgM beta2-
glycoprotein 
1 Antibody 
- positive > 
20 
Row - 
Totals 
SLE 34 4 38 
% 89.47% 10.53%   
SLE + APS syndrome 11 3 14 
% 78.57% 21.43%   
Totals 45 7 52 
  Fisher exact test (1-side)  0,275 
 
 
 
 
 
In both groups anti-ds DNA antibody is mostly positive. There is no dependence 
between the anti-ds DNA autoantibody variable and one of the patient groups (P = 0.911). 
(Table 11) 
 
Table 11. Observed anti-ds DNA antibody frequencies 
2-Way Summary Table: Observed Frequencies  
  
anti-ds 
DNA - 
positive 
anti-ds 
DNA - 
negativ 
(<30) 
Row - 
Totals 
SLE 27 17 44 
% 61.36% 38.64%   
SLE + APS syndrome 15 10 25 
% 60.00% 40.00%   
Totals 42 27 69 
Chi-Square test  0.911 
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It is established that there is no statistically significant difference in complement 
component levels of C3 and C4 between patients diagnosed with SLE and patients diagnosed 
with SLE and secondary APS (C3: P = 0.686; C4: P = 0.371). (Table 12) 
 
Table 12. Difference of C3 and C4 complement levels between Group 1 and Group 2 
T-tests; Grouping: Category; Group 1: SLE Group 2: SLE + APS syndrome 
  Mean - SLE 
Std.De
v. - 
SLE 
Mean 
- 
SLE+ 
APS 
syndr
ome 
Std.De
v. - 
SLE+ 
APS 
syndr
ome 
t-
value df p 
Valid 
N - 
SLE 
Valid 
N - 
SLE+ 
APS 
syndr
ome 
C3 0.88 0.26 0.90 0.23 -0.41 72 0.686 45 29 
C4 0.14 0.08 0.12 0.07 0.90 72 0.371 45 29 
 
 
 
 
 
 
It is established that positive anti-ds DNA antibody titers correlate with a statistically 
significant difference in C3 and C4 complement component levels in the group of patients 
with SLE (C3: P = 0.007; C4: P = 0.023). (Table 13) 
 
Table 13. C3 and C4 complement levels in SLE patients regarding anti-ds DNA titer 
Category = SLE T-tests; Grouping: anti-ds DNA; Group 1: positive Group 2: negative 
(<30) 
  
Mean 
- 
positiv
e 
Std.De
v. - 
positiv
e 
Mean 
- 
negati
ve 
(<30) 
Std.De
v. - 
negati
ve 
(<30) 
t-
value df P 
Valid 
N - 
positiv
e 
Valid 
N - 
negati
ve 
(<30) 
C3 0.79 0.27 1.01 0.19 -2.84 42 0.007 27 17 
C4 0.12 0.08 0.17 0.08 -2.37 42 0.023 27 17 
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There is no statistically significant difference between anti-ds DNA antibody titers and 
complement component levels in patients with SLE and secondary APS. (C3: P = 0.065; C4: 
P = 0.077). If the p-value was raised to 10% there would be a statistically significant 
difference. (Table 14) 
 
Table 14. C3 and C4 complement levels in SLE with secondary APS syndrome patients    
                 regarding anti-ds DNA titer 
Category = SLE + APS syndrome T-tests; Grouping: anti-ds DNA; Group 1: positive 
Group 2: negative (<30) 
  
Mean 
- 
positiv
e 
Std.De
v. - 
positiv
e 
Mean 
- 
negati
ve 
(<30) 
Std.De
v. - 
negati
ve 
(<30) 
t-
value df P 
Valid 
N - 
positiv
e 
Valid 
N - 
negati
ve 
(<30) 
C3 0.83 0.20 1.00 0.23 -1.94 23 0.065 15 10 
C4 0.11 0.05 0.16 0.09 -1.85 23 0.077 15 10 
 
 
 
 
 
 
Amongst patients diagnosed with SLE, there is a statistically significant difference in 
complement component levels of C3 and C4 in patients with positive IgM aCL antibody titers 
and negative titers (C3: P = 0.036; C4: P = 0.004). (Table 15) 
 
Table 15. C3 and C4 complement levels in SLE patients regarding IgM aCL antibody titer 
Category = SLE T-tests; Grouping: IgM aCL Antibody; Group 1: negative < 12.5 Group 2: 
positive 
  
Mean 
- 
negati
ve < 
12.5 
Std.De
v. - 
negati
ve < 
12.5 
Mean 
- 
positiv
e 
Std.De
v. - 
positiv
e 
t-
value df P 
Valid 
N - 
negati
ve < 
12.5 
Valid 
N – 
positiv
e 
C3 0.94 0.23 0.75 0.31 2.18 38 0.036 28 12 
C4 0.17 0.08 0.09 0.07 3.08 38 0.004 28 12 
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Amongst patients diagnosed with SLE and secondary APS there is no difference in 
complement component levels in patients with increased IgM aCL antibody titers compared 
negative titers (C3: P = 0.656; C4: P = 0.526). (Table 16) 
 
Table 16. C3 and C4 complement levels in SLE with secondary APS syndrome patients    
                 regarding IgM aCL antibody titers 
Category = SLE + APS syndrome T-tests; Grouping: IgM aCL Antibody; Group 1: 
negative < 12.5 Group 2: positive 
  
Mean 
- 
negati
ve < 
12.5 
Std.De
v. - 
negati
ve < 
12.5 
Mean 
- 
positiv
e 
Std.De
v. - 
positiv
e 
t-
value df P 
Valid 
N - 
negati
ve < 
12.5 
Valid 
N - 
positiv
e 
C3 0.91 0.21 0.87 0.21 0.45 23 0.656 18 7 
C4 0.12 0.05 0.11 0.05 0.64 23 0.526 18 7 
 
 
 
 
Testing the difference in C3 and C4 complement component levels amongst patients 
with increased IgG aCL antibody titers and titers within the normal range we can conclude 
that there is a statistically significant difference for C4 complement levels (P = 0.004), while 
there is no statistically significant difference for C3 complement component levels (P = 
0.052) in patients diagnosed with SLE. It should be noted that the latter P-value of 0,052 
almost reaches that of a statistically significant finding of 0.05. (Table 17) 
 
Table 17.  C3 and C4 complement levels in SLE patients regarding IgG aCL antibody titer 
Category = SLE T-tests; Grouping: IgG aCL Antibody; Group 1: negative Group 2: positive 
  
Mean 
- 
negati
ve <15 
Std.De
v. - 
negati
ve <15 
Mean 
- 
positiv
e 
Std.De
v. - 
positiv
e 
t-value df P 
Valid 
N - 
negati
ve <15 
Valid 
N - 
positiv
e 
C3 0.93 0.23 0.75 0.32 2.00 39 0.052 30 11 
C4 0.16 0.08 0.10 0.08 2.14 39 0.038 30 11 
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Testing the difference in C3 and C4 complement component levels amongst patients 
with increased IgG aCL antibody titers and titers within the normal range we can conclude 
that there is no statistically significant difference regarding patients with SLE and secondary 
APS (C3: P = 0.471; C4: P = 0.058). (Table 18) 
 
Table 18. C3 and C4 complement levels in SLE with secondary APS syndrome patients      
                 regarding IgG aCL antibody titers 
Category = SLE + APS syndrome T-tests; Grouping: IgG aCL Antibody; Group 1: negative 
Group 2: positive  
  
Mean 
- 
negati
ve <15 
Std.De
v. - 
negati
ve <15 
Mean 
- 
positiv
e 
Std.De
v. - 
positiv
e 
t-
value df P 
Valid 
N - 
negati
ve <15 
Valid 
N - 
positiv
e 
C3 0.91 0.22 0.85 0.19 0.73 22 0.471 14 10 
C4 0.13 0.04 0.10 0.05 2.00 22 0.058 14 10 
 
 
 
 
We examined the correlation of C3 and C4 complement component levels and anti-ds 
DNA antibody titers in patients diagnosed with SLE. (Table 19) 
 
This correlation matrix shows a negative and statistically significant correlation of C3 
complement component levels and anti-ds DNA antibody titers (r=-0.673; P <0.001), and the 
same applies for the correlation of C4 and anti-ds DNA antibody titers (r=-0.4571; P <0.002). 
This means that high anti-ds DNA antibody titers correlate with lower levels of complement 
components. (Table 19) 
 
Table 19. Correlation of C3 and C4 complement component levels and anti-ds DNA antibody  
                 titer in patients with SLE 
Category = SLE Correlations; Marked correlations are significant at p < .05000 N=43  
  anti-ds DNA 
C3 -0.6734 
  P <0.000 
C4 -0.4571 
  P =0.002 
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The correlation is shown graphically in a scatter plot. (Figure 4 and 5) 
 
 
Figure 4. Correlation of C3 and anti-ds DNA in SLE patients 
 
 
Figure 5. Correlation of C4 and anti-ds DNA in SLE patients 
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The correlation matrix shows a negative and statistically significant correlation of C4 
complement component levels and anti-ds DNA antibody titers (r=-0.4856; P = 0.014), while 
correlation of C3 and anti-ds DNA antibody titers is not statistically significant (P <0.052) in 
patients with SLE and secondary APS. However, it should be noted that the latter P-value of 
0,052 almost reaches that of a statistically significant finding. (Table 20) 
 
Table 20. Correlation of C3 and C4 complement component levels and anti-ds DNA antibody  
                 titer in patients with SLE and secondary APS 
Category = SLE + APS Syndrome; Correlations; Marked correlations are significant at p < .05000 
N=25  
  anti-ds DNA 
C3 -0.3925 
  P =.052 
C4 -0.4856 
  P =.014 
 
 
The correlation is shown graphically in a scatter plot. (Figure 6) 
 
 
Figure 6. Correlation of C4 and anti-ds DNA in SLE with secondary APS patients 
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5. DISCUSSION
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According to the results obtained in this study, SLE and hence SLE with secondary 
APS, is more prevalent in the female population, which is consistent with common findings 
so far (32). In our study mean complement levels of C3 for the group diagnosed with SLE 
were significantly lowered, while C4 complement component levels in both groups, and C3 
levels in the SLE with secondary APS group were found within the reference interval, even 
though in all cases at the lower end of the normal range. This tendency correlates with other 
recent findings that stated hypocomplementemia or a tendency for complement components at 
the lower end of the normal range to be commonly occurring in both APS and SLE (6,18). 
Consequently, we hypothesized that patients with both SLE and APS have a higher 
complement consumption and therefore lower complement component levels compared to 
patients with SLE only. A potentially statistically significant difference might have led us to 
the assumption that the complement component levels play an even more significant role in 
the occurrence of SLE with secondary APS compared to SLE alone and this might have 
emphasized its importance for future diagnostic and therapeutic purposes. Contrary to our 
hypothesis, there is no statistically significant difference in the complement component levels 
between the two groups in our study. According to the data collected the complement 
component levels are almost equal in both groups, with mean levels for C3 of 0.88 and 0.9 
and for C4 of 0.14 and 0.12 in patients with SLE and patients with SLE and secondary APS, 
respectively. 
The data of this study also show that in patients diagnosed with SLE positive anti-ds 
DNA antibody titers correlate with a statistically significant difference in C3 and C4 levels, 
and this correlation was found to be negative, which means the higher the anti-ds DNA titer, 
the lower the complement component levels. This correlation is also true for C4 complement 
component levels and anti-ds DNA titers, but not for C3 levels, however the P-value of 
<0.052 approaches that of a statistically significant finding, in the group of patients with SLE 
and secondary APS. Other studies have found that high ds-DNA antibody titers and decreased 
complement levels are more commonly present in SLE flares and active disease compared to 
remission or inactive disease, which is also points to the importance of appropriate timing 
when it comes to sampling blood from patients in order to achieve meaningful research 
results (33). If the same applies for APS and SLE with secondary APS has not been 
determined yet and could be a topic of future research 
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The implementation of complement component levels as biomarkers for APS with or 
without SLE have not been established yet and are the subject of ongoing trials like the 
PROMISSE study (Predictors of Pregnancy Outcome: Biomarkers in Antiphospholipid 
Syndrome and Systemic Lupus Erythematosus), which will end in 2019 and will hopefully 
lead to promising results. Particularly for SLE, only C3 and C4 serum levels have been 
traditionally used to evaluate the diseases, but recent research has shown that rather the 
complement products than the substrates, termed serum cell-bound complement activation 
products, might be more sensitive and specific than conventional serum C3 and C4 levels to 
assess disease activity. This might also be relevant in prospective research and reveal new 
insights for the relationship between complement component levels and autoimmune diseases 
like SLE and APS (34,35). 
As discussed beforehand around 30-40% of patients with SLE are aPL positive. One 
of our aims was to determine the association between aPLs and complement components in 
SLE without APS and SLE with secondary APS. We found that patients who were diagnosed 
with SLE without secondary APS and simultaneously had positive aCL titers, had statistically 
significant lower levels of complement components compared to patients who were aCL 
negative. These results are consistent with the results of a study conducted 2016 in Norway, 
that also confirmed significantly lower complement levels in aPL positive patients compared 
to aPL negative patients (36). This finding may reflect a higher C3 and C4 consumption 
owing to more prominent complement activation in aCL positive SLE patients compared to 
aCL negative SLE patients. These results are conceptually in line with our first hypothesis 
that patients with SLE and secondary APS might have higher complement consumption 
compared to patients with SLE without secondary APS, even though we could not confirm 
that hypothesis with our results. The association between complement components and aPLs 
in patients with SLE and secondary APS has not been a subject of research yet and should be 
investigated in the future. Our part of the study that dealt with the association between 
complement components and aPLs in patients with SLE and secondary APS could not 
produce any statistically significant results. This might also be the result of our study 
limitations that we will evaluate at the end of this discussion. 
Recent research, as outlined in the introduction, has determined that the complement 
system, especially the anaphylatoxins like C5a and MAC, are key mediators in the 
pathogenesis of SLE and APS, and some therapeutic approaches targeting complement 
components, most notably the C5 inhibitor eculizumab, have already been experimentally 
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proved to work on murine models and have even been successfully conducted in some human 
cases diagnosed with SLE and APS (18,37–41). These findings emphasize and support the 
importance of further determining the significance of the complement system for SLE and 
APS. 
There was no information about the current disease activity at the time when the 
laboratory data included in this cross-sectional study were collected. We could approach this 
problem by doing a prospective study and collecting blood samples at times of active disease 
and therefore obtain more consistent, meaningful and comparable data about complement 
levels. Since both SLE and SLE with secondary APS are rare clinical pictures and Croatia 
does not offer as many patients as other more populated countries, the small simple size might 
be a limitation to the validity of our results. In keeping with this limitation, a third control 
group with for example the diagnosis of primary APS, could yield even more conclusions 
about the association between complement component levels and specific autoantibodies in 
SLE and APS. Due to a lack of patients, this could not be accomplished in our hospital 
setting. Also the incomplete availability of all the variables intended to obtain from eligible 
patients is a flaw that could be improved in a future study. Ultimately the lack of prior 
research on the exact topic of this study leaves us without the possibility to compare our 
results to other study results and the conclusions drawn from this study are therefore limited. 
Further research could outline the importance of the complement system and its 
association with specific autoantibodies in the pathogenesis and occurrence of APS and SLE 
even more and newly obtained information could eventually be used as a path to new 
diagnostic criteria, means to monitor the disease and innovative treatment options.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6. CONCLUSION
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1. Patients with SLE without APS have statistically significantly lowered C3 complement 
component levels. Patients with SLE and patients with SLE and secondary APS show a 
general tendency for complement component levels to be at the lower end of the normal 
range. 
 
2. In both groups anti-ds DNA antibody was mostly positive. There was no statistically 
significant difference between anti-ds DNA antibody titers and complement component levels 
between patients with SLE without secondary APS and patients with SLE and secondary 
APS.  
 
3. SLE patients have a statistically significant difference in complement levels with positive 
anti-ds DNA titers. Positive anti-ds DNA titers correlate negatively with C3 and C4 levels in 
patients with SLE without APS, and the same applied to the C4 levels in patients with SLE 
and secondary APS. 
 
4. In SLE patients, there was a significant difference in C3 and C4 levels with positive IgM 
aCL antibody titers, while for IgG aCL antibody titers, the same applied to C4 complement 
levels.  
 
Some of the results are consistent with published reports so far, while other relations are 
surprising. Particularly interesting are the correlations between complement and 
anticardiolipin antibodies, most notably IgM, that suggest a complex role of the complement 
system in autoimmune events. We hold that we have highlighted the complexity of 
complement component levels in regard to diseases such as SLE and SLE with secondary 
antiphospholipid syndrome, especially in relation to specific autoantibodies. 
Further research with an improved study design that overcomes the limitations described 
beforehand is necessary in order to yield more insight about the role of complement or 
complement activation products and their relation to specific antibodies and the course of 
SLE and APS. 
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8. SUMMARY
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Objectives: To compare levels of complement components between patients with SLE and 
patients with SLE and secondary antiphospholipid syndrome and investigate their relation 
with levels of anti-dsDNA and anticardiolipin antibodies. 
Materials and methods: A cross-sectional study was conducted at the Department of 
Rheumatology and clinical Immunology of the University Hospital Split (KBC Split). 
Included were 74, 45 with SLE and 29 with SLE and secondary APS. Patient data were 
obtained from the database at the Department for Rheumatology and Immunology as well as 
at the Institute for Laboratory Diagnostics, KBC Split. The investigated laboratory parameters 
are: antinuclear antibodies, anti-ds DNA antibodies, C3, C4, IgG, IgM, IgA, Lupus 
Anticoagulant, IgG and IgM anticardiolipin antibodies, IgG and IgM beta2-gylcoprotein 1 
antibodies.  
 
Results: All patients with SLE had decreased C3 values, while the C4 values were within the 
reference interval. Patients with SLE and secondary APS had C3 and C4 levels within the 
reference interval but at the lower limit. In both groups, aCL IgG and IgM antibodies were 
mostly negative, whereas anti-ds DNA antibodies were mostly positive. Anti-ds DNA was 
statistically significantly correlated with C3 (P <0.001) and C4 (P <0.002) in SLE patients 
without APS, the same correlation was confirmed in patients with SLE and secondary APS 
for C4 complement levels (P = 0.014). Only the group of patients with SLE without 
secondary APS show a correlation of C3 and C4 with a positive titer of IgM aCL antibodies 
(C3: P = 0.036; C4: P = 0.004) as well as C4 with IgG aCL antibodies (P = 0.004). There is 
no statistically significant difference in complement component levels of C3 and C4 between 
patients diagnosed with SLE without APS and patients diagnosed with SLE and secondary 
APS (C3: P = 0.686; C4: P = 0.371). 
Conclusion: In SLE patients, lowered levels of C3 were confirmed as well as the correlation 
of reduced complement levels with the specific autoantibody dsDNA. The expected 
difference between C3 and C4 complement levels was not confirmed between patients with 
SLE without APS and patients with SLE and secondary APS. Interesting are the correlations 
of complement and anticardiolipin antibodies, in particular IgM, that suggest a complex role 
of complement in autoimmune events and the need for further research. 
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Naslov: USPOREDBA RAZINA KOMPONENTI KOMPLEMENTA U SISTEMSKOM 
LUPUSU I SEKUNDARNOM ANTIFOSFOLIPIDNOM SINDROMU U ODNOSU NA 
SPECIFIČNA AUTOPROTUTIJELA 
Ciljevi: Usporediti razine komponenti komplementa između bolesnika sa sistemskim 
lupusom (SLE) i bolesnika sa SLE i sekundarnim antifosfolipidnim sindromom te istražiti 
njihovu povezanost  s razinama anti-dsDNA i antikardiolipinskih protutijela. 
Materijali i metode: Presječna studija provedena je u Zavodu za reumatologiju i kliničku 
imunologiju KBC-a Split. Uključena su 74 bolesnika, 45 sa SLE i 29 sa SLE i sekundarnim 
APS. Podatci o bolesnicima dobiveni su iz baze podataka Zavoda za reumatologiju i 
imunologiju te Zavoda za laboratorijsku dijagnostiku, KBC Split. Istraživani laboratorijski 
parametri su:  antinuklearna antitijela, anti-ds DNA antitijela, C3, C4, IgG, IgM, IgA, Lupus 
antikoagulans, antikardiolipinska protutijela klase IgG i IgM,beta2-glikoprotein protutijela 
klase IgG i IgM.  
 
Rezultati: Svi bolesnici sa SLE imali su snižene vrijednosti C3 dok su vrijednosti C4 bile 
unutar referentnih vrijednosti. Bolesnici sa SLE i sekundarnim APS  imali su C3 i C4 unutar 
referentnih vrijednosti ali na donjoj granici. U obje skupine aCL IgG i IgM protutijela su bila 
većinom negativa dok su  anti-ds DNA protutijela bila većinom pozitivna. Anti-ds DNA  su 
statistički značajno korelirala s razinama C3 (P <0.001) i  C4 (P <0.002) u skupini SLE 
bolesnika bez APS, ista korelacija je potvrđena u bolesnika sa SLE i sekundarnim APS za 
razinu C4 (P = 0.014). Također  je samo u skupini bolesnika sa SLE bez APS potvrđena 
značajna korelacija  C3 i C4  s pozitivnim titrom IgM a CL protutijela (C3: P = 0.036; C4: P 
= 0.004) kao i IgG aCL protutijela samo s titrom C4 (P = 0.004 ). Nije potvrđena  statistički 
značajna razlika u razinama C3 i C4  bolesnika sa SLE bez APS i SLE sa APS (C3: P = 
0.686, C4: P = 0.371). 
Zaključci: U bolesnika sa SLE potvrđene su snižene razine C3 te povezanost sniženih razina 
komplementa sa specifičnim autoprotutijelom ds DNA. Nije potvrđena očekivana razlika u 
razinama C3 i C4 između bolesnika sa SLE bez APS i bolesnika sa SLE i APS. Zanimljive su 
korelacije komplementa s antikardiolipinskim protutijelima, posebice IgM što upućuje na 
složenu ulogu komplementa u autoimunim zbivanjima i potrebu daljnjih istraživanja. 
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